Targeting Cost Effective Large Scale Manufacturing For r-AAV Vectors By Transient Transfection Using Pall's Allegro STR Bioreactor
By Marie Laure Collignon, David Mainwaring, Andreia Pedregal, Adrien Cariou, Brian Mullan, Cedrick Rousseaux, and Sophie Blondel
To date there is huge pressure on biomanufacturing facilities due to the high demand for the manufacturing of gene therapy products such as recombinant adeno-associated viral (rAAV) vectors under current good manufacturing conditions.
Yposkesi, part of SK pharmteco, is a leading CDMO in Europe for rAAV and rLV production and is investing significantly to improve the productivity of viral vector manufacturing processes.
Yposkesi has evaluated Pall’s Allegro STR 50 bioreactor for its usability and performance by conducting a proof of concept study with a triple transient transfection rAAV process, using a proprietary transfection reagent, a high productivity HEK293T cell line, and a custom medium. The process tech transfer was performed by keeping the power input per unit volume (P/V) and the superficial gas velocity constant.
The user friendliness of Pall’s Allegro STR bioreactor is a strong point, for both biocontainer installation and software operations, and the close collaboration between Yposkesi and Pall scientific supporting teams, resulted in a favorable increase in production yields.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.